Liminal BioSciences announces completion of the plan of arrangement with Structured Alpha LP. loom.ly/e_tMVNE; read more below:-

Liminal Biosciences receives final court order for plan of arrangement with Structured Alpha LP. loom.ly/_-QOHdI; read more below:-

Liminal Biosciences Shareholders approve plan of arrangement with Structured Alpha LP. loom.ly/jmuqJRc; read more below:

Liminal Biosciences files amended schedule 13E-3 and supplement to the management information circular. loom.ly/kQOr7Eo; read more below:

Liminal Biosciences obtains interim order for proposed arrangement with Structured Alpha LP; read more: loom.ly/7jFE1zk

Liminal BioSciences Reports Second Quarter Financial Results 2023. Read more; loom.ly/1NoU9H8

Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP. Under the terms of the agreement Liminal BioSciences minority shareholders to receive US$8.50 in cash per share. Read more: loom.ly/pwBQlZ4

Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders. Read more: loom.ly/1QQWzcU

We are pleased to have nominated a lead preclinical candidate, LMNL6326, for the development of its OXER1 antagonist program, targeting the treatment of eosinophil-driven diseases, and provided an R&D update on all three of our #GPCR development programs. lnkd.in/eHmkqfDD

Liminal BioSciences Reports First Quarter Financial Results 2023. Read More: loom.ly/wjPxZvQ